Executive Director, Clinical Nurse Educator and Patient Advocacy TerSera Therapeutics
IV cetirizine is a new, recently approved 2nd generation IV antihistamine. This session will provide a detailed product overview, detailed review of the phase III trial in which IV cetirizine was FDA approved, and discuss further patient subset analysis that will help identify appropriate patients for IV cetirizine.
Learning Objectives:
Describe the FDA approved indication for IV cetirizine.
Compare and contrast the safety profile of IV cetirizine vs. IV diphenhydramine.
Compare the clinical outcomes of IV cetirizine vs IV diphenhydramine in the treatment of acute urticaria.